Abbvie Inc

Chart & Performance

D1W1MN

P/E

61.88

P/S

5.54

EPS

2.75

Div Yield, %

3.64%

Shrs. gr., 5y

2.78%

Rev. gr., 5y

10.65%

Revenues

54.32b

-6.44%

Net income

4.86b

-58.91%

CFO

22.84b

-8.44%

Dividend

Jan 15, 20251.64 USD/sh

Earnings

Jan 31, 2025

Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

URL

https://www.abbvie.com/

IPO date

Jan 02, 2013

Employees

50,000

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	54,318,000 -6.44%	58,054,000 3.30%
Cost of revenue	41,772,000	39,184,000
Unusual Expense (Income)
NOPBT	12,546,000	18,870,000
NOPBT Margin	23.10%	32.50%
Operating Taxes	1,377,000	1,632,000
Tax Rate	10.98%	8.65%
NOPAT	11,169,000	17,238,000
Net income	4,863,000 -58.91%	11,836,000 2.55%
Dividends	(10,539,000)	(10,043,000)
Dividend yield	3.84%	3.50%
Proceeds from repurchase of equity	(1,972,000)	(1,225,000)
BB yield	0.72%	0.43%
Debt
Debt current	7,191,000	4,136,000
Long-term debt	53,718,000	59,906,000
Deferred revenue
Other long-term liabilities	33,517,000	30,655,000
Net debt	47,789,000	54,572,000
Cash flow
Cash from operating activities	22,839,000	24,943,000
CAPEX	(777,000)	(695,000)
Cash from investing activities	(2,009,000)	(623,000)
Cash from financing activities	(17,222,000)	(24,803,000)
FCF	11,115,000	17,413,000
Balance
Cash	12,816,000	9,229,000
Long term investments	304,000	241,000
Excess cash	10,404,100	6,567,300
Stockholders' equity	(3,250,000)	2,636,000
Invested Capital	107,311,000	108,577,000
ROIC	10.35%	15.05%
ROCE	12.06%	16.64%
EV
Common stock shares outstanding	1,773,000	1,778,000
Price	154.97 -4.11%	161.61 19.36%
Market cap	274,761,810 -4.38%	287,342,580 19.42%
EV	322,587,810	341,947,580
EBITDA	21,244,000	27,337,000
EV/EBITDA	15.18	12.51
Interest	2,224,000	2,230,000
Interest/NOPBT	17.73%	11.82%